04 Small Animal Imaging Facility

项目摘要：小动物成像设施（SAIF） 小动物成像设施（SAIF）的使命是通过提供癌症 中心成员拥有强大的成像技术和成功整合所需的专业知识， 影像科学应用于临床前癌症研究。Dr. John D. Hazle担任主任，James A. 班克森担任联席董事。该设施包括教师专家，受过专门培训的工作人员，以及最先进的 成像仪器，其中大部分是在癌症中心的其他地方无法获得的。SAIF有3个 校园内设有独立的站点，以确保所有癌症中心成员都能方便地访问。SAIF成像 实验室位于北校区，毗邻小动物饲养场， 南校区动物园，以及南校区3号研究楼。SAIF的教职员工都可以 支持临床前癌症研究中成像的各个方面，从提案和实验设计到 数据采集、分析、解释和演示。目前，SAIF有21个独特的成像片段， 为小动物优化的设备和支持动物的全套辅助设备 在实验之前，期间和之后成像设备包括3台高场磁共振 扫描仪、低场永磁磁共振扫描仪、动态核极化系统 用于产生超极化磁共振剂的微计算机断层摄影系统、正电子 发射断层扫描/单光子发射计算机断层扫描/计算机断层扫描扫描仪，2台小型- 动物辐射研究平台，2个超声系统（1个能够进行光声成像）， 光声成像系统，一个机柜X射线系统，6个光学成像系统，和一个原型磁 弛豫测量系统（作为研究协议的一部分借用）。在此期间，MD安德森资助 资本设备5，918，344美元，通过NCI共享或高端项目获得约110万美元 仪器赠款。每年的业务资金为195，521美元（20%）来自CCSG，719，742美元（74%）来自CCSG。 计划收入和53，413美元（6%）的机构支持。在这6年的赠款期间，SAIF提供了一个 共有250名癌症中心成员，包括来自所有16个CCSG项目的研究人员。总共有87% 使用由同行评审资助，SAIF要求CCSG在第44年拨款200，057美元（20%）。整体 42年的使用量比上一个供资周期的平均使用量增加了2.7倍。支持181 在本报告所述期间，同行评审的出版物中，51篇（28%）发表在IF >10的期刊上，119篇发表在IF >10的期刊上。 (66%），发表在那些与IF >5。具体目标是：目标1：保持广泛的最新技术水平 支持癌症中心临床前成像需求的成像仪器和专职人员 目标2：在规划、采购和分析方面提供咨询、培训和支持， 目标3：开发和实施新的技术和方法，以提高准确性 以及临床前癌症研究中定量成像生物标志物的精确性。

PROJECT SUMMARY: SMALL ANIMAL IMAGING FACILITY (SAIF) The mission of the Small Animal Imaging Facility (SAIF) is to advance cancer research by providing cancer center members with powerful imaging technologies and the expertise necessary to successfully integrate imaging sciences into preclinical cancer research. Dr. John D. Hazle serves as director, and Dr. James A. Bankson serves as co-director. The facility includes faculty experts, specially trained staff, and state-of-the-art imaging instrumentation, most of which is not available anywhere else in the cancer center. The SAIF has 3 separate sites across the campus to ensure convenient access to all cancer center members. SAIF imaging laboratories are located on the North Campus adjacent to and contiguous with the small animal vivarium, inside the South Campus Vivarium, and in South Campus Research Building #3. SAIF faculty and staff are available to support all aspects of imaging in preclinical cancer research, from proposal and experiment design through data acquisition, analysis, interpretation, and presentation. Currently, the SAIF has 21 unique pieces of imaging equipment optimized for small animals and a full complement of ancillary equipment for support of animals before, during, and after experiments. The imaging equipment includes 3 high-field magnetic resonance scanners, a low-field permanent magnet magnetic resonance scanner, a dynamic nuclear polarization system for generating hyperpolarized magnetic resonance agents, a microcomputed tomography system, a positron emission tomography/single-photon emission computed tomography/computed tomography scanner, 2 small- animal radiation research platforms, 2 ultrasound systems (1 capable of photoacoustic imaging), a dedicated photoacoustic imaging system, a cabinet X-Ray system, 6 optical imaging systems, and a prototype magnetic relaxometry system (on loan as part of a research agreement). During this grant period, MD Anderson has funded $5,918,344 in capital equipment, and approximately $1.1M has been obtained through NCI Shared or High-end Instrumentation grants. Annual operational funding is $195,521 (20%) from the CCSG, $719,742 (74%) from program income, and $53,413 (6%) of institutional support. During this 6-year grant period, the SAIF served a total of 250 cancer center members, including investigators from all 16 CCSG programs. A total of 87% of all usage was peer-review funded, and the SAIF is requesting $200,057 (20%) from the CCSG in grant Yr44. Overall use has increased 2.7-fold in Yr42 over the average use in the prior funding cycle. The SAIF supported 181 peer-reviewed publications during this reporting period, with 51 (28%) published in journals with IF >10 and 119 (66%) published in those with IF >5. The specific aims are: Aim 1: To maintain a broad range of state-of-the-art imaging instrumentation and dedicated staff that support the preclinical imaging needs of cancer center members; Aim 2: To provide consultation, training and support in the planning, acquisition, and analysis of imaging data; and Aim 3: To develop and implement new technologies and methods that improve the accuracy and precision of quantitative imaging biomarkers in preclinical cancer research.